Next Article in Journal
The association between cytomegalovirus infection and aging process
Previous Article in Journal
Analysis of antidepressant prescribing tendencies in Lithuania in 2003–2004
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Legal assessment of current situation on orphan patients in Lithuania

Department of Biolaw, Faculty of Law, Mykolas Romeris University, Lithuania
Medicina 2008, 44(8), 571; https://doi.org/10.3390/medicina44080074
Received: 10 January 2008 / Accepted: 16 June 2008 / Published: 21 June 2008
After Lithuania joined the European Union, the Regulation (EC) No. 141/2000 on orphan medicinal products and Commission Regulation (EC) No. 847/2000 came into force as part of national legislation. Member States must adopt specific measures to increase knowledge on rare diseases and to improve their detection, diagnosis, and treatment. The aim of this article was to present and to assess the current legal situation on orphan patients and their treatment in Lithuania, to identify legislation gaps, and to propose some ideas how to facilitate the solution of the existing problems in this field. For this purpose, European Union and Lithuanian legal documents on rare medicinal products are examined using a comparative method. With reference to inventory of Member States’ incentives for rare diseases in national level, the most important issues, which orphan patients face to in Lithuania, are singled out. In Lithuania, the situation of orphan patients in terms of protection of patient rights is insufficiently determined. The access to effective health care services or approved therapies in some cases is restricted. Working relationships between genetic services and various clinical specialists as well as with those in primary care are not legally determined; the number of clinical trials aimed at orphan medicinal products is low. These results suggest a need for awareness raising among Lithuanian Government, health care specialists, patient organizations about the importance to improve practical implementation of European Union legislation and progressive experience of some European countries in this field.
Keywords: rare diseases; orphan patients; orphan medicinal products; legislation; patient rights rare diseases; orphan patients; orphan medicinal products; legislation; patient rights
MDPI and ACS Style

Špokienė, I. Legal assessment of current situation on orphan patients in Lithuania. Medicina 2008, 44, 571.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop